The serum level of CTGF was correlated with the fibrosis stage in patients with FALD but not in those with NAFLD, indicating that it may be a good surrogate marker for estimating the liver fibrosis stage in patients with FALD. The gene discussed is CCN2; the disease is metabolic dysfunction-associated steatotic liver disease.